Customize
Quick Links
Past Events

Accreditation/
Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Astellas and Medivation, Inc., Bayer HealthCare Pharmaceuticals, and sanofi-aventis U.S.
About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies


Resources

PER Pulse™ Recap

Three PER Pulse™ Recaps presenting key topics from the 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, which was held on March 14, 2015.



PER Pulse™ Recap

PER Pulse™ Recap
Medical Writer: Beth Cameron, PhD


1 of 3
PER Pulse™ Recap
8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

The Community Practice Connections: 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is a series of short video interviews with leading experts in the treatment of prostate cancer and other genitourinary malignancies, in which they address a variety of questions commonly faced by practicing community oncologists. This first of 3 PER Pulse™ Recaps focuses on the strategies for newly diagnosed and early prostate cancer.

Below are some clinical pearls and highlights from the activity:

  • According to Dr Leonard Gomella, biomarkers are of particular importance for patients for whom active surveillance, rather than active treatment, is being considered, as they allow the subdivision of risk stratification beyond standard clinical and histopathological parameters.
  • Dr Robert Dreicer explans that because that the primary therapy options for patients with early-stage disease have relatively equivalent outcomes, the decision comes down to which modality has an adverse event profile most acceptable to the individual patient.
  • Dr Gomella also discusses the current viewpoints on PSA screening for prostate cancer, and the controversy surrounding it.


2 of 3
PER Pulse™ Recap
8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

The Community Practice Connections: 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is a series of short video interviews with leading experts in the treatment of prostate cancer and other genitourinary malignancies who address a variety of questions commonly faced by practicing community oncologists. This second of 3 PER Pulse™ Recaps focuses on the strategies for advanced prostate cancer.

Below are some highlights from this case-based activity:

  • According to Dr Daniel Petrylak, a patient with high-volume bone metastases at diagnosis may be appropriate for combination treatment with androgen blockade and docetaxel
  • Dr Petrylak discusses why sipuleucel-T might be an appropriate option if, after androgen blockade and docetaxel, this patient were to progress with asymptomatic metastases and relatively low overall rise of prostate-specific antigen. He reviews treatment options that would be available during this patient's disease progression.
  • Dr Robert Dreicer describes circumstances under which sequential therapy with enzalutamide and followed by abiraterone (or vice versa) may be appropriate for an individual patient.


3 of 3
PER Pulse™ Recap
8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

The Community Practice Connections: 8th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies is a series of short video interviews with leading experts in the treatment of prostate cancer and other genitourinary malignancies who address a variety of questions commonly faced by practicing community oncologists. This third of 3 PER Pulse™ Recaps focuses on the treatment strategies for renal cell carcinoma.

Below are some highlights from this activity:

  • According to Primo N. Lara Jr, MD, PhD, prognostic features can be used to classify patients into risk categories that help guide treatment decisions.
  • When a patient with metastatic kidney cancer first presents in his office, Dr Lara is already considering the trajectory of multiple treatment choices past first-line therapy and explains that there is no data to support that the response to first-line therapy will predict response to later treatment.
  • Dr Lara acknowledges that there are many new agents for renal cell carcinoma, but these agents have limited diversity, falling into either mTOR or anti-angiogenic categories. He is hopeful that the checkpoint inhibitors targeting PD-1 or PD-L1 will lead to positive trials that not only increase the rates of response and progression-free survival, but overall survival, as well.


Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


This activity is not approved for AMA PRA Category 1 Credit™.

This activity is supported by educational grants from Astellas and Medivation, Inc., Bayer HealthCare Pharmaceuticals, and sanofi-aventis U.S.






Become a Member

Forgot Password?
Filter By